Bindarit
Alternative Names: AF-2838Latest Information Update: 24 Oct 2021
At a glance
- Originator Angelini Group
- Class Analgesics; Anti-inflammatories; Antirheumatics; Indazoles; Propionates; Small molecules
- Mechanism of Action Chemokine CCL2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Coronary artery restenosis; Diabetic nephropathies; Lupus nephritis; Pancreatitis; Rheumatoid arthritis
Most Recent Events
- 22 Jun 2012 Bindarit is available for licensing as of 22 Jun 2012. http://www.angelinipharma.com
- 30 Apr 2011 Angelini Group completes a phase II trial in Coronary artery restenosis prevention in Italy (NCT01269242)
- 26 Oct 2006 Discontinued - Phase-II for Rheumatoid arthritis in Italy (unspecified route)